Cancer drug development is costly and fraught with failure, but these three companies have successfully navigated clinical trials and as a result, each has a chance at winning FDA approval of their drugs in 2017.
A stunning clinical setback leaves this biotech in disarray. What's in store for Alnylam and its shareholders?
Our healthcare contributors think these pharma companies deserve a closer look from investors.
Regeneron Pharmaceuticals stock is far more expensive than its peers. Here's why.
Arrowhead cuts a deal with the biotech heavyweight Amgen.
The antisense pioneer has a big lead over its competitors in more ways than one.
Looking for cheap stocks that will pay you to own them? Here are three companies you might want to consider.
Let's look at the challenges and opportunities facing these Big Pharma stocks to see which is most attractive now.
The development-stage biotech may not have any earnings, but it's producing plenty of data to keep investors interested.
Inherent advantages in the healthcare system for drugmakers are fueling soaring drug prices.